Jonathan Gardner
Senior Reporter at BioPharma Dive
Senior reporter, BioPharma Dive. Father of 1, husband of 1, son of 2, brother of 2, uncle of 7. Opinions are mine. RTs are not endorsements. Darn good runner.
Articles
-
3 days ago |
biopharmadive.com | Delilah Alvarado |Jonathan Gardner |Ned Pagliarulo
New drugs, however heralded, take time to embed into clinical care. Enhertu, the powerful antibody-drug conjugate from Daiichi Sankyo and AstraZeneca, was first approved in the U.S. in 2019, before the world had even heard of a novel coronavirus.
-
4 days ago |
biopharmadive.com | Jonathan Gardner
CHICAGO — A Johnson & Johnson drug currently used for advanced prostate cancer can help keep the disease from progressing in men who are at earlier stages and have certain genetic mutations, according to newly unveiled data from a Phase 3 clinical trial. Results from this trial, named Amplitude, were released Tuesday at the American Society of Clinical Oncology’s meeting in Chicago.
-
5 days ago |
biopharmadive.com | Delilah Alvarado |Jonathan Gardner |Ned Pagliarulo
CHICAGO — The American Society of Clinical Oncology’s annual meeting is a forum for data. On Monday, it was also the backdrop to oncology’s latest deal, when Bristol Myers Squibb and BioNTech announced a multibillion-dollar alliance around a newly in-vogue drug. BioNTech’s drug is a bispecific antibody that simultaneously targets the proteins PD-L1 and VEGF.
-
6 days ago |
biopharmadive.com | Ned Pagliarulo |Jonathan Gardner
Funding cancer research isn't usually a political flashpoint. But as the Trump administration signals its desire to drastically cut the budget of the National Cancer Institute, the American Society of Clinical Oncology is finding itself forced to defend what is usually a bipartisan policy. "If implemented, these cuts would be devastating to the pace and progress of cancer research in America," ASCO CEO Clifford Hudis said in a Friday statement.
-
1 week ago |
biopharmadive.com | Jonathan Gardner
AstraZeneca and Daiichi Sankyo’s targeted cancer medicine Enhertu helped participants in a late-stage clinical trial with a type of advanced gastric cancer live longer than those who received a commonly prescribed, two-drug regimen involving chemotherapy. The finding, detailed Saturday at the American Society of Clinical Oncology’s annual meeting, gives physicians a clearer choice for when patients’ disease progresses after initial treatment.
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →X (formerly Twitter)
- Followers
- 3K
- Tweets
- 9K
- DMs Open
- No
Coming out of hibernation (see me at BlueSky!) to look at the $SRPT stream and remind everybody ....
1/ "It's always good news for $SRPT!" is a phrase I began tweeting back in the days when $SRPT was in a neck-and-neck race with $BMRN to get the first exon-skipping agent on the market.
I love these M&A drawings. $TEVA https://t.co/ppVQSrBtRq
It would be an interesting end to the PARP story if it turned out that, like iniparib, none of the PARPs actually inhibited PARP. $AZN $GSK $CLVS $MRK